Total Funding
74
73
Total FundingSeries B raised
Growth Score
-1 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
11179
Sironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases.
- Nasir Khan: Senior Vice President of Preclinical DevelopmentPast Role: Pfizer, Chief of Non-Clinical Safety Officer
- Gary Ingenito: Senior Vice President of Clinical DevelopmentPast Role: Catalyst Pharmaceuticals, Chief Medical Officer
About the Company
Sironax is a clinical-stage biotechnology company that develops novel products and treatments for age-related degenerative diseases. The company is focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. They aim to shift the treatment paradigm for
age-related degenerative disease to improve the lives of millions of patients and their families around the world.
Sironax was founded in 2017 and is based in Beijing, China.
